Serveur d'exploration Tocilizumab - Analysis (2020)

Index « AbsEn.i » - entrée « failure »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
fails < failure < failures  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 30.
[0-20] [0 - 20][0 - 30][20-29][20-40]
Ident.Authors (with country if any)Title
000014 (2020) Puja Mehta ; Jessica J. MansonWhat Is the Clinical Relevance of TNF Inhibitor Immunogenicity in the Management of Patients With Rheumatoid Arthritis?
000023 (2020) Yehyun Park [Corée du Sud] ; Jae Hee Cheon [Corée du Sud]Update on the Treatment of Behcet's Disease of the Small Bowel with Biologic Agents.
000053 (2020) Jean-Marie Michot [France] ; Laurence Albiges [France] ; Nathalie Chaput [France] ; Veronique Saada [France] ; Fanny Pommeret [France] ; Franck Griscelli [France] ; Corinne Balleyguier [France] ; Benjamin Besse [France] ; Aurélien Marabelle [France] ; Florence Netzer [France] ; Mansouria Merad [France] ; Caroline Robert [France] ; Fabrice Barlesi [France] ; Bertrand Gachot [France] ; Annabelle Stoclin [France]Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report
000074 (2020) Grégoire Ducoux [France] ; Arthur Guerber [France] ; Cécile-Audrey Durel [France] ; Bouchra Asli [France] ; Jehane Fadlallah [France] ; Arnaud Hot [France]Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis/Renal Failure, and Organomegaly (TAFRO) Syndrome with Bilateral Adrenal Hemorrhage in Two Caucasian Patients
000116 (2020) Xi-Ying Wang [République populaire de Chine] ; Fen Zhang [République populaire de Chine] ; Chi Zhang [République populaire de Chine] ; Liang-Rong Zheng [République populaire de Chine] ; Jian Yang [République populaire de Chine]The Biomarkers for Acute Myocardial Infarction and Heart Failure
000128 (2020) Sophie Testa [Italie] ; Oriana Paoletti [Italie] ; Matteo Giorgi-Pierfranceschi [Italie] ; Angelo Pan [Italie]Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients
000169 (2020) Maria Antonietta Barbieri [Italie] ; Giuseppe Cicala [Italie] ; Paola Maria Cutroneo [Italie] ; Elisabetta Gerratana [Italie] ; Caterina Palleria [Italie] ; Caterina De Sarro [Italie] ; Ada Vero [Italie] ; Luigi Iannone [Italie] ; Antonia Manti [Italie] ; Emilio Russo [Italie] ; Giovambattista De Sarro [Italie] ; Fabiola Atzeni [Italie] ; Edoardo Spina [Italie]Safety Profile of Biologics Used in Rheumatology: An Italian Prospective Pharmacovigilance Study.
000175 (2020) Bernhard Maisch [Allemagne]SARS-CoV-2 as potential cause of cardiac inflammation and heart failure. Is it the virus, hyperinflammation, or MODS?
000177 (2020) Kaveh Hajifathalian ; Srihari Mahadev ; Robert E. Schwartz ; Shawn Shah ; Kartik Sampath ; Felice Schnoll-Sussman ; Robert S. Brown Jr ; David Carr-Locke ; David E. Cohen ; Reem Z. SharaihaSARS-COV-2 infection (coronavirus disease 2019) for the gastrointestinal consultant
000210 (2020) Thomas Koudstaal ; Karin A. Boomars ; Mirjam KoolPulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: An Immunological Perspective
000227 (2020) Lauren E. Lee [États-Unis] ; Bradley W. Beeler [États-Unis] ; Brendan C. Graham [États-Unis] ; Andrew P. Cap [États-Unis] ; Nay Win [Royaume-Uni] ; Frederick Chen [Royaume-Uni]Posttransfusion hyperhemolysis is arrested by targeting macrophage activation with novel use of Tocilizumab.
000244 (2020) Przemysław Błyszczuk [Suisse, Pologne] ; Zoltan Szekanecz [Hongrie]Pathogenesis of ischaemic and non-ischaemic heart diseases in rheumatoid arthritis
000246 (2020) Christian Guder [Allemagne] ; Sascha Gravius [Allemagne] ; Christof Burger [Allemagne] ; Dieter C. Wirtz [Allemagne] ; Frank A. Schildberg [Allemagne]Osteoimmunology: A Current Update of the Interplay Between Bone and the Immune System
000276 (2020) Giacomo Bellani [Italie] ; Tài Pham [France] ; John G. Laffey [Irlande (pays)]Missed or delayed diagnosis of ARDS: a common and serious problem
000286 (2020) Tiago Torres [Portugal] ; Luis Puig [Espagne]Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic
000305 (2020) Susanne H. C. Baumeister [États-Unis] ; Benedetta Rambaldi [États-Unis, Italie] ; Roman M. Shapiro [États-Unis] ; Rizwan Romee [États-Unis]Key Aspects of the Immunobiology of Haploidentical Hematopoietic Cell Transplantation
000326 (2020) Phillip Sommer ; Elvedin Lukovic [États-Unis] ; Eliot Fagley [États-Unis] ; Dustin R. Long [États-Unis] ; Julia B. Sobol [États-Unis] ; Katherine Heller ; Vivek K. Moitra [États-Unis] ; Ronald Pauldine [États-Unis] ; Michael F. O Onnor ; Sajid Shahul ; Mark E. Nunnally ; Avery TungInitial Clinical Impressions of the Critical Care of COVID-19 Patients in Seattle, New York City, and Chicago
000344 (2020) Sadaf Atiqi [Pays-Bas] ; Femke Hooijberg [Pays-Bas] ; Floris C. Loeff [Pays-Bas] ; Theo Rispens [Pays-Bas] ; Gerrit J. Wolbink [Pays-Bas]Immunogenicity of TNF-Inhibitors
000349 (2020) Benjamin Corden ; Eleonora Adami ; Mark Sweeney ; Sebastian Schafer ; Stuart A. CookIL‐11 in cardiac and renal fibrosis: Late to the party but a central player
000385 (2020) Gaëlle Vial [France] ; Anaïs De Pouilly [France] ; Laetitia Scouppe [France] ; Bruno Pereira [France] ; Claire Daien [France] ; Cédric Lukas [France] ; Adeline Ruyssen-Witrand [France] ; Pascale Vergne-Salle [France] ; Christophe Richez [France] ; Anne Tournadre [France]Factors influencing the choice of biologic therapy following Rituximab in patients with rheumatoid arthritis: A retrospective study using propensity score.
000432 (2020) Kosuke Ebina [Japon] ; Toru Hirano [Japon] ; Yuichi Maeda [Japon] ; Wataru Yamamoto [Japon] ; Motomu Hashimoto [Japon] ; Koichi Murata [Japon] ; Tohru Takeuchi [Japon] ; Koji Nagai [Japon] ; Yonsu Son [Japon] ; Hideki Amuro [Japon] ; Akira Onishi [Japon] ; Sadao Jinno [Japon] ; Ryota Hara [Japon] ; Masaki Katayama [Japon] ; Keiichi Yamamoto [Japon] ; Atsushi Kumanogoh [Japon] ; Makoto Hirao [Japon]Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/2020/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/AbsEn.i -k "failure" 
HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/AbsEn.i  \
                -Sk "failure" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    2020
   |étape=   Analysis
   |type=    indexItem
   |index=    AbsEn.i
   |clé=    failure
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021